Skip to main content
. 2019 Dec 18;12(1):1699768. doi: 10.1080/19420862.2019.1699768

Figure 4.

Figure 4.

Dose-dependency of acMMAE and unconjugated MMAE PK for the eight vc-MMAE ADCs.

A. acMMAE clearance vs dose

B. Dose-normalized AUCinf at Cycle 1 of unconjugated MMAE vs dose

Open cycle: observed data, AUCinf: area under the concentration–time curve from time zero to infinity, acMMAE: antibody-conjugated MMAE, ADC1 = Pinatuzumab vedotin (CD22); ADC2 = Polatuzumab vedotin (CD79b); ADC3 = DEDN6526A (ETBR); ADC4 = DMOT4309A (MsLN); ADC5 = DMUC5754A (MUC-16); ADC6 = DNIB0600A (Napi2b); ADC7 = DSTP3086S (Steap1); ADC8 = DFRF4539A (FcRH5).